Innovative Therapy Pipeline Cantargia specializes in antibody-based therapies targeting IL1RAP, with ongoing clinical development of Nadunolimab (Phase II) for cancer and CAN10 (Phase I) for autoimmune and inflammatory diseases, indicating active growth opportunities in the biotech and pharma sectors.
Strategic Industry Engagement The company actively participates in high-profile industry conferences such as AACR and Van Lanschot Kempen's Life Sciences Conference, providing avenues for networking, partnership development, and visibility to potential collaborators and investors.
Recent Leadership Expansion Recent appointments of a new CEO and a Chief Medical Officer highlight organizational growth and a focus on strengthening scientific and strategic expertise, which can attract partners looking for committed and experienced biotech collaborators.
Partnership & Asset Acquisition Otsuka Pharmaceutical's recent acquisition of assets related to CAN10 demonstrates the company's potential to attract major pharmaceutical partners interested in innovative autoimmune and cancer therapies.
Funding & Market Presence Despite a modest funding level of $2.6 million, Cantargia's active engagement in conferences and strategic partnerships positions it as a promising candidate for additional investment and collaboration opportunities.
Cantargia AB uses 8 technology products and services including Google Hosted Libraries, Craft CMS, CookieScript, and more. Explore Cantargia AB's tech stack below.
| Cantargia AB Email Formats | Percentage |
| First.Last@cantargia.com | 89% |
| First.MiddleLast@cantargia.com | 8% |
| LastFirst@cantargia.com | 1% |
| First.Middle@cantargia.com | 2% |
Biotechnology ResearchSkåne, Sweden11-50 Employees
Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.
Company Overview
Funding & FinancialsCantargia AB has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jun 17, 2025 in the amount of $2.6M.
Funding & FinancialsCantargia AB has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jun 17, 2025 in the amount of $2.6M.
1-888-653-2347 
support@leadiq.com